Neutralizing Antibody Response to SARS-CoV-2 Variants After Two mRNA COVID-19 Vaccine Doses in a Cohort of Patients with Inflammatory Bowel Disease from a Southern Italy Tertiary Hospital
Authors:
- Dario GenoveseDario Genovese
- Daniele BrinchDBDaniele Brinch
- Stefano MuscarellaSMStefano Muscarella
- Marica SaladinoMSMarica Saladino
- Lucio CarrozzaLCLucio Carrozza
- Chiara CunsoloCCChiara Cunsolo
- Giuseppa Luisa SanfilippoGSGiuseppa Luisa Sanfilippo
- Emanuele AmodioEmanuele Amodio
- Maria CappelloMaria Cappello
- Donatella FerraroDFDonatella Ferraro
Open Access
- 26 February 2025
- journal article
- research article
- Published by MDPI AG in Healthcare
- Vol. 13 (5) , 508
Abstract
Introduction: Inflammatory bowel diseases (IBDs) require immunosuppressive drugs like biologics. All IBD patients, including those on biological therapy, should be vaccinated against COVID-19, according to the ECCO recommendations. IBD patients on anti-TNF treatment exhibited lower COVID-19 vaccine responses; however, SARS-CoV-2 variant neutralizing antibody titers have been seldom studied. Methods: IBD patients and healthcare professionals (control group) were tested for COVID-19 vaccine immunogenicity by neutralizing antibody titers against Wild-Type SARS-CoV-2 and its variants. IBD patients were assigned to no treatment/mesalamine, anti-TNF biologic therapy, or non-anti-TNF biologic therapy. The study was performed in a tertiary hospital in Palermo, Sicily, from May to July 2021. Results: In total, 107 IBD patients and 41 healthcare workers were enrolled. A total of 46 patients received mesalamine or no medication, 28 received anti-TNF biologics, and 33 received non-anti-TNF biologics. No significant differences were found in age, gender, or timing of blood sampling post vaccination. Omicron neutralizing activity was markedly reduced in all groups (p < 0.001). The group of patients on anti-TNF biologics showed lower neutralizing antibody titers against Alpha, Delta, and Gamma strains than every other group analyzed. Conclusions: IBD patients on anti-TNF drugs have a reduced serological response to the SARS-CoV-2 vaccine, with the Omicron variant not being neutralized. This highlights the necessity for tailored vaccine strategies for these patients.Keywords
This publication has 20 references indexed in Scilit:
- Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel DiseasesVaccines, 2022
- Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseasesJCI Insight, 2022
- Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 VariantsNew England Journal of Medicine, 2022
- COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control studyThe Lancet Gastroenterology & Hepatology, 2022
- Lower Serologic Response to COVID-19 mRNA Vaccine in Patients With Inflammatory Bowel Diseases Treated With Anti-TNFαGastroenterology, 2021
- Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBDGut, 2021
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesCell, 2021
- Management of Patients With Crohn’s Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International MeetingGastroenterology, 2020
- Risk of Serious and Opportunistic Infections Associated With Treatment of Inflammatory Bowel DiseasesGastroenterology, 2018
- Guidelines for Immunizations in Patients With Inflammatory Bowel DiseaseInflammatory Bowel Diseases, 2004